Hepatitis B Foundation President Dr. Chari Cohen is quoted in a powerful new story about hepatitis B in The New Yorker. You can read it here.

Thomas Tu, PhD

thomas Tu 3

Group Leader, Storr Liver Centre, Westmead Institute for Medical Research, Australia 

Dr. Thomas Tu is a molecular biologist focusing on the persistence of cccDNA and the pathogenesis linked to integrated HBV DNA. He is particularly passionate about developing a HBV cure and mitigating the associated liver cancer, as he himself lives with chronic Hepatitis B.  

Dr. Tu is the Secretary for Australian Centre for Hepatitis Virology (ACHV), the premier Australian society for hepatitis virus researchers; a board member of Hepatitis Australia, guiding the strategic direction of the peak national advocacy body for people with liver disease; and the founder and Director of HepBCommunity.org (a global support network for people affected with HBV), guiding people through their HBV diagnosis and linking them with trustworthy scientific and medical information. 

Read the journal picks of the month from our Emerging Scholars Scientific and Medical Advisory Board here.